SL
PACB icon

Stevard LLC’s Pacific Biosciences PACB Stock Holding History

Stevard LLC’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-33,753
Closed -$333K – 131
2020
Q3 		$333K Hold
33,753
– – 0.14% 98
2020
Q2 		$116K Buy
+33,753
New +$115K 0.06% 157

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Stevard LLC's PACB Position: Q4 2020 in Review

Stevard LLC sold out of Pacific Biosciences (PACB) in Q4 2020, closing a stake of 33,753 shares — an estimated $333K sold.

Stevard LLC first reported a position in PACB in Q2 2020 and held it in 2 quarters. The position peaked at $333K in Q3 2020. 210 funds tracked by Wall St. Rank hold PACB as of Q4 2020.

  • Stevard LLC reported no remaining Pacific Biosciences position as of Q4 2020 after selling out during the quarter.
  • Stevard LLC sold 33,753 Pacific Biosciences shares in Q4 2020, an estimated $333K.
  • Stevard LLC first reported a position in Pacific Biosciences in Q2 2020 and held it in 2 quarters.
  • Stevard LLC's Pacific Biosciences position peaked at $333K in Q3 2020.
  • 210 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2020.

Based on Stevard LLC's 13F filing for Q4 2020, filed 12 Feb 2021.